Bergamot Cholesterol Randomized Trial: What the Evidence Says

Quick Answer

Bergamot Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Obesity is a multifactorial disease defined as abnormal or excessive fat accumulation that presents a risk to health because it is a major risk factor for several noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, and several types of cancer. [Pujia Carmelo (2026); evidence level 1]
• Furthermore, obesity and its associated health problems have a significant economic impact on the global healthcare system. [Pujia Carmelo (2026); evidence level 1]
• Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, primarily driven by a combination of non-modifiable (gender and family history) and modifiable (e.g., dyslipidemia, hypertension, smoking, diabetes, and obesity) risk factors. [Carpenito Myriam (2025); evidence level 3]
• Among modifiable risk factors, low-density lipoprotein cholesterol (LDL-C) is recognized as the most significant contributor to atherosclerosis. [Carpenito Myriam (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For bergamot cholesterol randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Pujia Carmelo (2026). Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. DOI: 10.1111/obr.70094. PMCID: PMC13243342. PMID: 41572527. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13243342/
• Carpenito Myriam (2025). Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects. DOI: 10.3390/nu17111871. PMCID: PMC12158049. PMID: 40507140. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12158049/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.